Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn researchers to continue work on tapeworm

As a result of a recent large-scale global survey, tapeworms, a class which encompasses more than 5,000 species, are now one of the most well-known...

| By Kelley Gipson

New Haven emerges as biopharma city

Thirty years ago, the idea of starting a biotech venture in Connecticut was rare, if not unheard of. The obvious biotech hotbeds in the United...

| By Kelley Gipson

BioXcel to study role for Apple Watch re agitation

BioXcel Therapeutics has announced a strategic plan to investigate the development of using wearable digital device technology, such as the Apple Watch, with the goal of...

| By Kelley Gipson

Lamont applauds Alexion expansion plans

Governor Ned Lamont is applauding an announcement made by Alexion Pharmaceuticals that it plans to invest $10 million to expand its Global Product Development lab...

| By Kelley Gipson

InveniAI expands its flagship platform, AlphaMeld™

InveniAI® Corporation has expanded its flagship platform, AlphaMeld™. This expansion will provide a suite of products to facilitate the democratization of data analysis across the...

| By Kelley Gipson

BioCT welcomes Analoui and Boustany to Board

BioCT welcomes two new members to its Board of Directors. Mostafa Analoui, Ph.D., is Executive Director of Venture Development and Technology Incubation Program (TIP) at...

| By Kelley Gipson

BI wins FDA approval for lung disease medicine

The FDA has approved Boehringer Ingelheim’s Ofev (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients...

| By Kelley Gipson

SpringWorks announces IPO

SpringWorks Therapeutics reports the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00...

| By Kelley Gipson

Melinta names Sanfillipo interim CEO

Melinta Therapeutics reports that Jennifer Sanfilippo has been named interim chief executive officer and director. Prior to this appointment, Ms. Sanfilippo served as senior vice...

| By Kelley Gipson

ABCT information sessions scheduled

Accelerator for Biosciences in Connecticut, ABCT, is a competitive entry, 6-month long program designed for entrepreneurial research students and faculty, MBA’s and MD’s interested in...